Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfill our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free more...
Author Details :
Volume : 7, Issue : 1, Year : 2021
Article Page : 112-117
Background: Primary open-angle glaucoma (POAG), fundamentally results from impaired or suboptimal drainage of aqueous humor from the eye through the trabecular meshwork and/or uveoscleral pathways.
Aim and Objectives: the purpose of our study was to compare the efficacy and safety of Brimonidine 0.2% plus Brinzolamide 1% versus Brimonidine 0.2% plus Timolol 0.5% in patients with Primary Open Angle Glaucoma.
Materials and Methods: A total of 81 subjects including 84 eyes in group I (brimonidine plus timolol) and 78 eyes in group II (brimonidine plus brinzolamide) with open angle glaucoma were enrolled. The detailed glaucoma examination was done. IOP measurements at 9 am, 12 pm and 3 pm, during week 2, 4, 8 and 12 were used to assess efficacy. Adverse events were recorded. The statistical test used were Chi-square test, Unpaired t-test and Paired t-test.
Results: Majority of patients in group I obtained an IOP reduction of >30% at 9.00 am 92.3%), 12.00 pm (91.3%) and 3.00 pm (86.2%) after 12 weeks of therapy. Majority of patients in group II obtained an IOP reduction of >30% at 9.00 am (86.8%), 12.00 pm (87.7%) and 3.00 pm (71.9%) after 12 weeks of therapy.
Conclusion: Both drugs can thus be useful as second line therapy in the management of patients with POAG uncontrolled on monotherapy. Moreover, each drug has provided significant mean IOP reduction after three month of therapy at all visits and at all times.
Keywords: Brinzolamide, Primary openangle glaucoma, Timolol.
How to cite : Jain K , Rastogi P S , Chander A , Ansari M , A comparative study of topical fixed dose combination of brimonidine (0.2%) plus brinzolamide (1%) versus brimonidine (0.2%) plus timolol (0.5%) in patients of primary open angle glaucoma. Indian J Clin Exp Ophthalmol 2021;7(1):112-117
Copyright © 2021 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)